FAMA Holdings International Corp. Receives F.D.A. Approval for Hemor~Rite Cryotherapy™

FAMA Holdings International Corp. receives F.D.A. approval for Hemor~Rite Cryotherapy™.

(PRWEB) October 28, 2005 -- FAMA Holdings International Corp., a Florida based medical device company and maker of the Hemor~Rite Cryotherapy™ medical device for treatment of hemorrhoids, announced today it has received U.S. Food and Drug Administration (FDA) 510k approval to market its new Hemor~Rite Cryotherapy™. Hemor~Rite Cryotherapy™ is an anatomically designed device for applying cold therapy (Cryotherapy) directly to the swollen hemorrhoidal veins of external hemorrhoids and the internal hemorrhoids within the rectal cavity. The direct application of cold provides prompt relief of itching, pain, and swelling. In addition, Hemor~Rite Cryotherapy™ is beneficial for the treatment of anal and perianal fissures due to the vasoconstriction and analgesia properties of the device. The device, which represents an important new addition to FAMA’s line of healthcare products, is expected to be available in retail stores by December. Currently, the device may be ordered directly from the company by calling the company at 1-866- HEMORITE (1-866-436-6747).

Frank Melendez, FAMA’s president and CEO, said, "Approval of our new Hemor~Rite Cryotherapy™ is an exciting development for us, because it will enable us to provide consumers with the most advanced hemorrhoid treatment available over the counter. Our medical device is unique due to the fact that the ergonomic design will provide prompt relief and provide a better living for those suffering from this ailment.” Over 46% of Americans suffer from hemorrhoids including individuals suffering from stress, pregnant women, weight lifters and others. Hemor~Rite Cryotherapy™ has been designed taking into consideration human anatomy and medical concepts of cryotherapy.

FAMA also manufactures and markets Colon-Rite ® a dietary supplement for support of normal colon function and plans to launch additional lines of dietary supplements within the next few months.

# # #